Rozlytrek (entrectinib capsules and oral pellets – Genentech) — Cigna
Pediatric Diffuse High-Grade Gliomas with NTRK gene fusion
Initial criteria
- Patient age < 18 years
- Tumor is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion
- EITHER medication is used as adjuvant therapy OR medication is used for recurrent or progressive disease
Approval duration
1 year